March 13th 2025
The multi-year strategic partnership is intended to support commercial demand of Viking Therapeutics’ GLP-1 candidate, VK2735.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
In Wake of Trump Tariffs, Lilly Plans New US Pharmaceutical Manufacturing Sites
February 26th 2025Previous domestic capital expansion commitments since 2020 had been made in Research Triangle Park and Concord, both in North Carolina; Kenosha County, Wisconsin; Lebanon, Indiana; and Lilly’s home city of Indianapolis.